QUANTITATIVE-DETERMINATION OF ACRIVASTINE AND PSEUDOEPHEDRINE HYDROCHLORIDE IN PHARMACEUTICAL FORMULATION BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND DERIVATIVE SPECTROPHOTOMETRY

in this study, fourth derivative spectrophotometry and high performanc e liquid chromatography (HPLC) have been used and described for the qu antitative determination of acrivastine (I) and pseudoephedrine hydroc hloride (II) in their pharmaceutical capsules form (Duact(R)). In the former method, d(4)A/d lambda(4) values were measured in methanol at 3 15 and 269 nm for (I) and (II) respectively. The relative standard dev iations (RSD) for the method were found to be 1.16% for (I) and 0.94% for (II). The latter method based on reversed phase HPLC system using LiChrosorb C18 analytical column. The mobile phase used for separation of (I), (II) and internal standard (p-hydroxymethylbenzoate) were the water/acetonitrile/methanol/perchloric acid/n-octylamine (500:130:25: 13:0.3 v/v) and the detection of the compounds in the capsules were at 260 nm using UV detector. The RSD for the HPLC method were determined to be 0.79 and 0.88% for (I) and (II) respectively. The proposed meth ods, which give thoroughly comparable data, are simple, rapid, and all ow precise and accurate results and could be used for commercial formu lations containing acrivastine and pseudoephedrine hydrochloride in co mbination. (C) 1998 Elsevier Science B.V. All rights reserved.